Lipocine Inc. Daily Stock Analysis

Daily Stock Analysis, LPCN, Lipocine Inc, priceseries

Lipocine Inc. Daily Stock Analysis
Stock Information
Open
1.48
Close
1.51
High
1.60
Low
1.45
Previous Close
1.50
Daily Price Gain
0.01
YTD High
1.60
YTD High Date
Mar 7, 2022
YTD Low
0.80
YTD Low Date
Jan 24, 2022
YTD Price Change
0.42
YTD Gain
38.53%
52 Week High
2.03
52 Week High Date
Mar 17, 2021
52 Week Low
0.80
52 Week Low Date
Jan 24, 2022
52 Week Price Change
0.09
52 Week Gain
6.34%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 13. 2017
3.68
Jun 26. 2017
3.91
9 Trading Days
6.17%
Link
LONG
Jul 10. 2017
4.13
Aug 1. 2017
4.79
16 Trading Days
16.09%
Link
LONG
Feb 26. 2018
1.31
Mar 12. 2018
1.49
10 Trading Days
13.52%
Link
LONG
Aug 30. 2018
1.42
Sep 20. 2018
1.52
14 Trading Days
7.37%
Link
LONG
Dec 31. 2018
1.30
Jan 22. 2019
1.59
14 Trading Days
21.97%
Link
LONG
Feb 28. 2019
1.74
Mar 27. 2019
2.09
19 Trading Days
19.94%
Link
LONG
Aug 12. 2019
1.90
Sep 11. 2019
2.99
21 Trading Days
57.44%
Link
LONG
Jun 19. 2020
0.96
Jul 13. 2020
1.23
15 Trading Days
27.67%
Link
LONG
Jul 30. 2020
1.51
Aug 19. 2020
2.06
14 Trading Days
36.30%
Link
LONG
Jan 19. 2021
1.76
Jan 26. 2021
1.89
5 Trading Days
7.39%
Link
LONG
Feb 8. 2022
1.00
Feb 24. 2022
1.12
11 Trading Days
12.19%
Link
Company Information
Stock Symbol
LPCN
Exchange
NasdaqCM
Company URL
http://www.lipocine.com
Company Phone
801 994 7383
CEO
Mahesh V. Patel
Headquarters
United States
Business Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, X1 84108
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001535955
About

Lipocine, Inc. engages in the research and development of treatment for use in men's and women's health through proprietary drug delivery technologies. It focuses on oral testosterone replacement therapy and preterm birth prevention. The company was founded on July 24, 2013 and is headquartered in Salt Lake City, UT.

Description

Lipocine Inc., a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy designed for twice-a-day dosing that has completed Phase 3 testing. The company's pipeline candidates also include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing that is in Phase 2 testing; and LPCN 1107, which has completed Phase 2 testing for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading